Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First Author: Philipp K. Buehler 

Journal/preprint name: medrxiv 

Paper DOI: https://doi.org/10.1101/2020.09.10.20191882 

Tags: Superinfections, critically ill COVID-19 patients, ICU, antibiotics 

Summary

Isolation of relevant respiratory bacteria associated with more severe disease course, prolonged ICU stay and use of ventilators in critically ill COVID-19 patients. Mainly gram-negative pathogens were isolated, in line with previous studies and the authors list the most frequently isolated bacteria and fungi detected. Authors conclude that, based on the superinfections identified, broad-spectrum antimicrobial therapy could be stopped and patients only treated if bacteria are detected, which may reduce the prevalence of drug-resistant bacteria. 

Research Highlights  

  1.  Clinically relevant bacterium or fungus was detected in 42.2% of patients (higher than previously recorded, although this could be due to strict sample collection schedule and the severely ill patients in the cohort) 

  1.  124 relevant microorganisms were detected in tracheobronchial secretions (TBS), but only seven different bacterial species in 12 positive blood culture pairs 

  1. On average clinically relevant pathogens were detected on day 10 after ICU admission 

  1. Multidrug resistant bacteria was detected in 22.2% of patients 

  1. Patients with pulmonary superinfections had substantially lower 28-day ventilator-free survival than those without and they were ventilated for significantly longer, had significantly longer stays in the ICU and increased hospitalization time. 

Impact for COVID-19 research:  

  • Identifying the bacterial strain means it can be treated specifically rather than with broad-spectrum antibiotics, resulting in a reduction of morbidity and mortality in COVID-19 patients  

Methodologies: 

  • Study TypeProspective Cohort Study  

Limitations: 

  • Small number of patients - Total of 45 patients, skewed towards male (77.8%) 

  • Majority of patients treated with empirical broad-spectrum antibiotic therapy at admission (>90%) 

  • Investigated only critically ill COVID-19 patients  

  • Single centre design